Dosage effect on uropathogenic Escherichia coli anti-adhesion activity in urine following consumption of cranberry powder standardized for proanthocyanidin content: a multicentric randomized double blind study by Howell, Amy B et al.
Howell et al. BMC Infectious Diseases 2010, 10:94
http://www.biomedcentral.com/1471-2334/10/94
Open Access RESEARCH ARTICLE
BioMed  Central
© 2010 Howell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Dosage effect on uropathogenic Escherichia coli 
anti-adhesion activity in urine following 
consumption of cranberry powder standardized 
for proanthocyanidin content: a multicentric 
randomized double blind study
Amy B Howell1, Henry Botto2, Christophe Combescure3, Anne-Béatrice Blanc-Potard4, Lluis Gausa5, 
Tetsuro Matsumoto6, Peter Tenke7, Albert Sotto4 and Jean-Philippe Lavigne*4,8
Abstract
Background: Ingestion of cranberry (Vaccinium macrocarpon Ait.) has traditionally been utilized for prevention of 
urinary tract infections. The proanthocyanidins (PACs) in cranberry, in particular the A-type linkages have been 
implicated as important inhibitors of primarily P-fimbriated E. coli adhesion to uroepithelial cells. Additional 
experiments were required to investigate the persistence in urine samples over a broader time period, to determine 
the most effective dose per day and to determine if the urinary anti-adhesion effect following cranberry is detected 
within volunteers of different origins.
Methods: Two separate bioassays (a mannose-resistant hemagglutination assay and an original new human T24 
epithelial cell-line assay) have assessed the ex-vivo urinary bacterial anti-adhesion activity on urines samples collected 
from 32 volunteers from Japan, Hungary, Spain and France in a randomized, double-blind versus placebo study. An in 
vivo Caenorhabditis elegans model was used to evaluate the influence of cranberry regimen on the virulence of E. coli 
strain.
Results: The results indicated a significant bacterial anti-adhesion activity in urine samples collected from volunteers 
that consumed cranberry powder compared to placebo (p < 0.001). This inhibition was clearly dose-dependent, 
prolonged (until 24 h with 72 mg of PAC) and increasing with the amount of PAC equivalents consumed in each 
cranberry powder regimen. An in vivo Caenorhabditis elegans model showed that cranberry acted against bacterial 
virulence: E. coli strain presented a reduced ability to kill worms after a growth in urines samples of patients who took 
cranberry capsules. This effect is particularly important with the regimen of 72 mg of PAC.
Conclusions: Administration of PAC-standardized cranberry powder at dosages containing 72 mg of PAC per day may 
offer some protection against bacterial adhesion and virulence in the urinary tract. This effect may offer a nyctohemeral 
protection.
Background
Ingestion of cranberry (Vaccinium macrocarpon Ait.) has
traditionally been utilized for prevention of urinary tract
infections (UTI). A recent systematic review concluded
t h a t  t h e r e  i s  s o m e  p o s i t i v e  c l i n i c a l  e v i d e n c e  t h a t  c o n -
sumption of cranberry juice can reduce the number of
symptomatic UTIs in women over a 12-month period [1].
Research suggests that consuming cranberry products
may prevent adhesion of certain Escherichia coli strains
to the uroepithelium [2-4], interfering with this impor-
tant initial step in the infection process [5]. The proan-
thocyanidins (PACs) in cranberry, in particular the A-
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type linkages have been implicated as important inhibi-
tors of primarily P-fimbriated E. coli adhesion to uroepi-
thelial cells in vitro [6-9] and ex vivo [10]. Cranberry PAC
extracts inhibited adhesion of E. coli in a linear, dose-
dependent fashion over a PAC concentration range of 75
to 5 μg/mL [9]. The PACs in cranberry contain unusual
double A-type linkages which may be important struc-
tural features in the anti-adhesion process [7]. In one
study, other food sources of PAC that contain only B-type
linkages (chocolate, grape, apple and green tea) were con-
sumed. However, they did not elicit ex vivo bacterial anti-
adhesion activity. Only cranberry juice with A-type PACs
prevented bacterial adhesion [11].
Several assays have been successfully utilized to detect
bacterial anti-adhesion activity of cranberry, including
mannose-resistant hemagglutination (MRHA) [3,7,9,12],
Gal-Gal receptor bead agglutination [3,6], bladder epithe-
lial cell adherence [2,3,9,12,13] and microplate-turbidity
[14]. Utilizing a bioassay to detect in vitro anti-adhesion
activity of whole cranberry products and isolated PACs is
useful for determining product integrity, however it does
not assess in vivo activity of the post-ingested cranberry
metabolites. Urinary bacterial anti-adhesion activity may
be a more biologically relevant marker for cranberry
ingestion as well as the effectiveness of consuming cran-
berry for prevention of UTI. A number of studies have
demonstrated an ex vivo bacterial anti-adhesion effect in
human urine following consumption of different cran-
berry products [11-13,15-17].
The current recommended daily dosage of cranberry
for UTI prevention is based on the efficacious levels that
have been administered in human intervention trials. A
commonly recommended amount of cranberry for UTI
prevention is daily consumption of 300 mL of cranberry
juice cocktail containing 36 mg proanthocyanidins mea-
sured by DMAC method, which clinically reduced bacte-
riuria and pyuria [18]. Formulations of cranberry in
powder form like tablets and capsules have demonstrated
activity in vitro [9], ex vivo [19] and in vivo [20,21]. How-
ever, additional human studies are needed to more com-
prehensibly establish the effective dose response range
for cranberry, utilizing products standardized for PAC
content. Standardization is important to establish prod-
uct integrity and shelf-life, and to formulate accurate test
materials for use in research studies. Criticism of early
studies on cranberry often cited lack of use of appropriate
standardized material, making conclusions and compari-
sons to other studies difficult [1]. Research indicates that
processing of cranberry into various products can impact
the PAC composition, which is very heterogeneous [22].
Molecular weight and location of the A-type linkages in
cranberry PACs could potentially impact the bacterial
anti-adhesion activity [23]. Thus, proper standardization
of cranberry products for PAC content and correlation of
the PAC level with anti-adhesion bioactivity may be
important to ensure that particular cranberry products
contain PACs that are efficacious.
A first double-blind, randomized, placebo-controlled
study of our team indicated a dose-dependent effect in ex
vivo  urinary bacterial anti-adhesion activity after con-
sumption of a PAC-standardized commercial cranberry
powder [12]. Anti-adhesion activity was measured in
urines 12 h after treatment regimes. Following these
results, additional experiments were required to investi-
gate the persistence in urine over a broader time period,
and to determine the most effective dose of PAC equiva-
lents per day. Further studies are also needed to deter-
mine if the urinary anti-adhesion effect following
cranberry is universal within the population or is specific
to certain ethnicities, dietary regimes, locations, etc. T o
address these issues, we conducted the present multi-
location randomized, double-blind versus placebo study
to evaluate additional dosage regimes and collection
time-periods following ingestion of the same PAC-stan-
dardized cranberry powder.
Methods
Even if cranberry is a supplement food, the study has
been approved by the different research ethics commit-
tees (1/Comité d'éthique Sud Méditerranée III, Nîmes,
France; 2/Comité Etico de Investigaciòn Clinica (CEIC)
de Fundació Puigvert, Barcelona, Spain; 3/Ethical com-
mittee of Jahn Ferenc South-Pest Teaching Hospital,
Hungary; 4/Ethics Committee of Medicine and Medical
Care, University of Occupational and Environmental
Health, Japan), in each country and has been conducted
according to the principles expressed in the Declaration
of Helsinki. Thirty-two female, sexually-active volunteers
over the age of 18, with normal renal function were
recruited through four urology departments in Japan
(Kyushu University Hospital), Hungary (South-Pest Hos-
pital, Budapest), Spain (Fundació Puigvert, Barcelona),
and France (Hôpital Foch, Suresnes) (eight volunteers/
department) to participate in this randomized, double-
blind, placebo-controlled cross-over study. Volunteers
were cleared through ethics committees and provided
informed consent. Exclusion criteria included antibiotic
use within six months prior to the study, pregnancy,
known allergy or intolerance of cranberry products, or
routine consumption of any food supplements consisting
of vitamins, minerals or trace elements. Throughout the
study, volunteers were instructed not to alter their dietary
or lifestyle habits in any way. However, during the capsule
consumption, volunteers were told to avoid all Vaccin-
ium-containing foods, drinks and supplements including
other forms of V. macrocarpon (cranberry), V. myrtillus
(bilberry or European blueberry), V. angustifolium (wild
or lowbush blueberry), V. corymbosum (highbush blue-Howell et al. BMC Infectious Diseases 2010, 10:94
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berry), and V. vitis-ideae (lingonberry). In addition, vol-
unteers were instructed to limit consumption of
chocolate, tea, grape and wine. All medications taken
during the study were reported to the doctor responsible
for following the study at each center.
The study was carried out using commercially available
capsules of cranberry powder (Urell®/Ellura™ Pharmatoka,
Rueil Malmaison, France) and capsules of placebo com-
posed of colloidal silica, magnesium stearate, cellulose
and gelatin. Capsules were opaque to conceal the color of
the contents. The PACs in the cranberry powder were
quantified by Brunswick Laboratories (Norton, MA)
using a colorimetric assay, an updated dimethylamino-
cinnamaldehyde method (DMAC method), taking advan-
tage of the selective colorimetric reaction between PACs
and DMAC after open column gel chromatography on
Sephadex® LH-20 (Amersham). The capsule dosages were
standardized to deliver 18 or 36 mg of PAC equivalents in
the cranberry powder.
The volunteers in Japan and Hungary received 0, 36 or
72 mg PAC equivalents per day and those in France and
Spain received 0, 18 or 36 mg PAC equivalents per day.
Each volunteer received successively three regimens
(always 2 capsules) distributed in random order, consist-
ing of: (1) cranberry (2 PAC dosage levels), or (2) placebo,
or (3) 1 capsule of cranberry at each PAC dosage and 1
capsule of placebo, with a washout period of at least one
week between each regimen. Volunteers consumed the
capsules in the morning at 8:00 AM. The first urines were
collected from 9:00 AM-2:00 PM following capsule con-
sumption, and pooled. The second collections were made
the following morning (8:00 AM). Pre-cranberry con-
sumption urines collections (0 h) were obtained at the
beginning of the study in each volunteer. Various biologi-
cal and physicochemical parameters of the urine samples
( c o l l e c t e d  a t  e a c h  r e g i m e n )  w e r e  m e a s u r e d  u s i n g  t h e
Multistix® (Bayer) system. Urines with an abundance of
leukocytes and nitrites were excluded. Remaining sam-
ples were centrifuged at 4000 g for 15 minutes, sterilized
by filtration (0.45 μm), separated in 3 aliquots and stored
at -20°C.
A uropathogenic E. coli strain previously isolated from
a patient with UTI (NECS978323) [12], with P-fimbriae
papG  and type-1 pili was utilized. To allow the direct
observation of adherent bacteria by fluorescence micros-
copy, NECS978323 was genetically modified to express
green fluorescent protein (GFP) using a pBBR-derived
non-mobilizable plasmid carrying a GFP expression cas-
sette [24]. Bacteria were grown in trypticase soy broth
(bioMerieux, Marnes La Coquette, France) or coloniza-
tion factor antigen agar for 16 h at 37°C to enhance
expression of P-fimbriae.
To insure product potency, the PAC-standardized cran-
berry powder was tested for in vitro uropathogenic bacte-
rial anti-adhesion activity prior to consumption by the
volunteers, utilizing a MRHA, to detect anti-adhesion
activity in uropathogenic P-fimbriated E. coli [11]. Briefly,
the anti-adhesion bioactivity of the powder was tested by
measuring the ability of the fractions to suppress aggluti-
nation of human red blood cells (HRBC) (A1, Rh+) fol-
lowing incubation with uropathogenic P-fimbriated E.
coli. Bacteria were suspended in phosphate-buffered
saline (PBS) solution at pH 7.0 at a concentration of 5 ×
108 bacteria/mL. The powder was dissolved in PBS at a
starting concentration of 60 mg/mL, and the pH adjusted
to neutrality with NaOH. A serial 2-fold dilution was pre-
pared, and each dilution (30 mL) was incubated with 10
mL of bacterial suspension on a 24-well polystyrene plate
for 10 min at room temperature on a rotary shaker. A 3%
v/v suspension of HRBCs in PBS was prepared, and 10
mL of the diluted blood was added to the test suspension.
The suspension was incubated for 20 min on a rotary
shaker at 21C and evaluated microscopically for the abil-
ity to prevent agglutination. The final dilution concentra-
tion was recorded at which agglutination suppression by
the cranberry fraction occurred. Wells containing bacte-
ria plus PBS, HRBC plus PBS, bacteria plus test fraction,
and HRBC plus test fraction served as negative controls
for agglutination, and wells containing bacteria plus
H R B C  s e r v e d  a s  a  p o s i t i v e  c o n t r o l  f o r  a g g l u t i n a t i o n .
Assays were performed in triplicates.
Urines were tested ex vivo for anti-adhesion activity
before and after the treatment regimes, utilizing two sep-
arate assays. The MRHA assay described above was mod-
ified by substituting urine for a cranberry solution.
Briefly, a 30-μL drop of each urine was incubated with 10
μL of the bacterial suspension on a 24-well polystyrene
plate for 10 min at 21C on a rotary shaker. The HRBCs
were added to the urines, incubated for 20 min on a
rotary shaker at 21C and evaluated microscopically for
the ability to prevent agglutination. If no agglutination
was observed, the urine was considered to contain anti-
adhesion metabolites and was recorded as possessing
Anti-Adhesion Activity (AAA). The results were
expressed as a percentage of anti-adhesion activity (0%
MRHA = 100% AAA, 50% MRHA = 50% AAA and 100%
MRHA = 0% AAA). Assays were repeated 4 times on trip-
licate urine samples and the standard error calculated.
In the second ex vivo urine assay, bacterial adhesion
was evaluated utilizing the human T24 epithelial cell-line
(ATCC HTB-4). A new technology was developed using
fluorescent NECS978323 to enhance detection of strain
adhesion. Monolayers of epithelial cells were grown at
37°C in McCoy's 5a medium containing 10% (v/v) fetal
calf serum, 1.5 mM glutamine, and antibiotics (50 U/mL
penicillin and 50 mg/mL of streptomycin), on coverslips
in 24-well Falcon tissue culture plates. Bacteria were
grown overnight in the urine samples containing 5% (v/v)Howell et al. BMC Infectious Diseases 2010, 10:94
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Luria broth. Bacterial were harvested by centrifugation,
resuspended at DO600 0.1 in McCoy's medium, added to
the tissue culture and incubated for 2.5 h at 37°C. After
washes with PBS, the cells were fixed with 4% paraform-
aldehyde, incubated 20 min at room temperature, and
examined under a fluorescent microscope. An adhesion
index (AI) corresponding to the mean number of adher-
ent bacteria per cell for 100 cells was calculated. This
index was expressed as the mean of at least three inde-
pendent assays.
C. elegans has been used to develop an easy model sys-
tem of host-pathogen interactions to identify basic evolu-
tionarily conserved pathways associated with microbial
pathogenesis. This test is based upon the capacity of E.
coli to be ingested by C. elegans nematodes leading to
infection and ultimately involving the killing death of the
worms [25]. Percentage of killed nematodes in presence
of the E. coli strain is an indirect marker of virulence
potential of this strain. The C. elegans infection assay was
carried out as described by Lavigne et al. [25] using Fer-
15 mutant line, which has a temperature sensitive fertility
defect. Fer-15 was provided by the Caenorhabditis
Genetics Center, which is funded by the NIH National
Center for Research Resources (NCRR). Briefly to syn-
chronize the growth of worms, eggs were collected using
the hypochlorite method. E. coli strain was grown for
overnight in human urine containing 5% (v/v) nematode
growth medium (NGM). Bacteria cells were harvested by
centrifugation, washed once and suspended in phosphate
buffered saline solution (PBS) at pH 7.0 at a concentra-
tion of 105 CFU/ml. NGM agar plates were inoculated
with 10 μl of strain and incubated at 37°C for 8-10 h.
P l a t e s  w e r e  a l l o w e d  t o  c o o l  t o  r o o m  t e m p e r a t u r e  a n d
seeded with L4 stage worms (20-30 per plate). Plates were
then incubated at 25°C and scored each day for live
worms under a stereomicroscope (Leica MS5). At least
three replicates repeated 5 times were performed for each
selected clone. A worm was considered dead when it no
longer responded to touch. Worms that died as a result of
becoming stuck to the wall of the plate were excluded
from the analysis. Lethal Time 50% (LT50) and death
(LT100) corresponded to time (in hours) required to kill
50% and 100% of the nematode population, respectively.
OP50 is an avirulent E. coli strain, an international stan-
dard food for nematodes used as control. The number of
bacteria within the C. elegans digestive tract was carried
out as described by Garsin et al. [26]. Five C. elegans were
picked at 72 h, and the surface bacteria were removed by
washing the worms twice in 4 μl drops of M9 medium on
a NGM agar plate containing 25 μg/ml gentamicin. The
nematodes were placed in a 1.5 ml Eppendorf tube con-
taining 20 μl of M9 medium with 1% Triton X-100 and
were mechanically disrupted by using a pestle. The vol-
ume was adjusted to 50 μl with M9 medium containing
1% Triton X-100 which was diluted and plated on Luria-
Bertani agar containing 50 μg/ml ampicillin. At least
three replicates were performed for each assay.
The quantitative variables were described by the
median values, the range and the mean, and standard
deviation. The qualitative variables were described by fig-
ures and percentages. The 95% confidence intervals were
assessed by the exact method of Clopper-Pearson. Fre-
quencies between AAA = 0% and AAA > 0% were com-
pared according to the criteria using a Fisher exact test
and the index values were compared using a Kruskal-
Wallis test. The index value was modelled by the hours,
the country and the dose using a Generalized Estimating
E q u a t i o n  m o d e l .  S u r v i v a l  c u r v e s  o f  t h e  w o r m s  w e r e
explored in a univariate analysis (Kaplan-Meier curves).
The median values of survival times were given. The sur-
vival curves were compared using log-rank test. A multi-
variate survival analysis was then performed (Cox
model). No procedure of variables selection was per-
formed. The assumptions of proportional hazards were
checked. A value of p ≤ 0.05 given by the SAS®/ETS soft-
ware (version 8.1) (SAS Institute Inc, Cary, NC, USA) was
considered statistically significant.
Results
In vitro anti-adhesion activity of cranberry powder
Bacterial anti-adhesion activity of the whole Urell®/
Ellura™ cranberry powder (measured by MRHA activity)
was 0.47 mg/mL (data not shown).
Effects detected by ex vivo assays
MRHA results indicated significant anti-adhesion activity
(AAA) in urines collected from volunteers that consumed
cranberry powder compared to placebo (p < 0.001) (Table
1). This inhibition was clearly dose-dependent, increasing
with the amount of PAC equivalents consumed in each
cranberry powder regimen. A peak of AAA was deter-
mined over the time course of the experiment. In urines
samples collected at 6 h, there was a significant difference
between the cranberry dosages containing 18 mg PAC
and those with either 36 or 72 mg PAC (p = 0.002); how-
ever, no statistical difference was detected between 36
and 72 mg PAC. In urine samples collected at 24 h, there
was a significant difference between the AAA of urines
belonging to patients who had consumed cranberry dos-
ages containing 72 mg of PAC (50% AAA) and the AAA
of urines belonging to patients who had consumed 18 or
36 mg of PAC (0 and 12% AAA, respectively) (p = 0.002)
(Table 1). In each country, similar results and trends were
detected (Table 1).
The ex vivo epithelial cell adhesion assay results indi-
cated a highly significant reduction in bacterial adhesion
to T24 cells compared to placebo (p < 0.001) following
the consumption of cranberry dosages containing 36 orH
o
w
e
l
l
 
e
t
 
a
l
.
 
B
M
C
 
I
n
f
e
c
t
i
o
u
s
 
D
i
s
e
a
s
e
s
 
2
0
1
0
,
 
1
0
:
9
4
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
3
4
/
1
0
/
9
4
P
a
g
e
 
5
 
o
f
 
1
1
Table 1: Urinary bacterial Anti-Adhesion Activity (AAA) detected with Mannose-resistant Hemagglutination (MRHA) assay (A) and urinary bacterial adhesion to T24 
cells (B) expressed as Adhesion Index (AI) following consumption of increasing doses of cranberry powder standardized for 18, 36 or 72 mg of proanthocyanidins 
(PAC) vs placebo by participants in the 4 countries.
AA A A P
Regimen Placebo 18 mg PAC 36 mg PAC 72 mg PAC 18 vs 36 36 vs 72 6 h vs 24 h Sp-Fr vs Ja-Hu
Spain (n = 8)
0 h 0% [0-0] 0% [0-0] 0% [0-0] ND
1-6 h 0% [0-0] 50% [50-100] 100% [50-100] ND 0.002 ND <0.001 <0.001
24 h 0% [0-0] 0% [0-0] 12.5% [0-50] ND 0.01 ND <0.001
France (n = 8)
0 h 0% [0-0] 0% [0-0] 0% [0-0] ND
1-6 h 0% [0-0] 50% [50-100] 75% [50-100] ND 0.005 ND <0.001
24 h 0% [0-0] 0% [0-0] 0% [0-0] ND NS ND <0.001
Japan (n = 8) <0.001
0 h 12.5% [0-50] ND 25% [0-50] 25% [0-50]
1-6 h 0% [0-0] ND 100% [100-100] 100% [100-100] ND NS <0.001
24 h 0% [0-0] ND 12.5% [0-50] 75% [50-100] ND 0.001 0.005
Hungary 
(n = 8)
0 h 0% [0-0] ND 0% [0-0] 0% [0-0]
1-6 h 0% [0-0] ND 87.5% [50-100] 100% [100-100] ND NS <0.001
24 h 0% [0-0] ND 25% [0-50] 25% [0-50] ND NS <0.001
Total (n = 32)
0 h 0.3% [0-0] 0% [0-0] 0.6% [0-50] 12.5% [0-50]
1-6 h 0% [0-0] 50% [50-100] 90.6% [50-100] 100% [100-100] 0.003 NS <0.001 ND
24 h 0% [0-0] 0% [0-0] 12.5% [0-50] 50% [50-100] 0.01 <0.001 <0.001 NDH
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B AI Median [Range] P
Regimen Placebo 18 mg PAC 36 mg PAC 72 mg PAC 18 vs 36 36 vs 72 6 h vs 24 h Sp-Fr vs Ja-Hu
Spain (n = 8)
1-6 h 18.5 [15-22] 8.5 [5-14] 5.0 [1-11] - <0.001 ND <0.001 <0.001
24 h 20.0 [18-22] 14.5 [10-18] 12.5 [5-17] - <0.001 ND <0.001
France (n = 8)
1-6 h 17.5 [15-28] 8.0 [5-16] 4.0 [2-10] - <0.001 ND <0.001
24 h 19.5 [18-25] 17.5 [12-22] 5.0 [2-10] - <0.001 ND <0.001
Japan (n = 8) <0.001
1-6 h 21.5 [18-28] - 5.0 [1-9] 3.5 [1-6] ND NS <0.001
24 h 25.5 [17-29] - 13.5 [10-18] 10.0 [2-15] ND 0.01 <0.001
Hungary (n = 8)
1-6 h 18.5 [15-22] - 2.0 [1-5] 1.0 [1-5] ND NS <0.001
24 h 20 [15-25] - 9.5 [5-25] 4.5 [2-10] ND <0.001 <0.001
Total (n = 32)
1-6 h 21.5 [15-28] 10.5 [5-16] 5.9 [1-11] 2.5 [1-6] <0.001 <0.001 <0.001 ND
24 h 22.3 [15-29] 16.0 [10-22] 14.5 [2-25] 9.9 [2-15] <0.001 <0.001 <0.001 ND
The results are representative of at least three independent trials. NS, not significant; ND, not determined. 0 h, pre-cranberry consumption collection
Table 1: Urinary bacterial Anti-Adhesion Activity (AAA) detected with Mannose-resistant Hemagglutination (MRHA) assay (A) and urinary bacterial adhesion to T24 
cells (B) expressed as Adhesion Index (AI) following consumption of increasing doses of cranberry powder standardized for 18, 36 or 72 mg of proanthocyanidins 
(PAC) vs placebo by participants in the 4 countries. (Continued)Howell et al. BMC Infectious Diseases 2010, 10:94
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72 mg of PAC (Table 1, Figure 1). There was a dose-
dependent decrease in bacterial adhesion with cranberry
intake. The Adhesion Index (AI) of bacteria grown in
urine samples collected after consumption of cranberry
with 36 or 72 mg PAC was significantly lower than the AI
following the dose with 18 mg PAC (p < 0.001). The mul-
tivariate analysis clearly confirmed a dosage effect for
each cranberry regimen vs placebo (p < 0.001) (Table 2).
AI of bacteria in urines collected at 6 h and at 24 h were
significantly different following all cranberry regimens (p
< 0.001). Interestingly, the AI at 24 h after cranberry
intake of 72 mg PAC equivalents remained significantly
low (AI median <10) compared to the other regimens (p <
0.001). The multivariate analysis confirmed a time depen-
dent-effect with the maximum effect at 6 h compared to
24 h (p < 0.001). The multivariate analysis demonstrated
an effect of patients' origin. When the data were adjusted
by hour and dose, results from Japan were significantly
different compared to the three other countries, with
higher AI (p < 0.001) (Table 2).
At 6 h for the 3 PAC equivalency doses, a significant
correlation between AAA results and AI results was
noted (p = 0.01, 0.04 and 0.04 for 18, 36 and 72 mg PAC).
This trend was not observed at 24 h for the 3 doses (p =
non significant, 0.94 and 0.10 for 18, 36 and 72 mg PAC).
Reduction of E. coli virulence
We evaluated the virulence potential of E. coli strain in
presence of different urines following consumption of
cranberry powder. The mean survival time (LT50) for
worms was significantly increased to 5-6 days with E. coli
grown in urine samples collected after cranberry intake
compared to LT50 for strain grown in urine samples col-
lected after placebo intake (3 days) (p < 0.001) (Table 3).
In urines collected after 6 h, no difference can be detected
between the virulence of E. coli strain grown in urines
collected after consumption of PAC.
In multivariate analysis, there was a significant effect of
PAC dose influencing the virulence of E. coli (HR = 1 for
placebo to HR = 0.32 for 72 mg): there was an inverse
Table 2: Multivariate analysis of results obtained to urinary bacterial adhesion to T24 cells expressed as adhesion index.
Parameters SD IC95% p p globale
inf sup
Countries France . . . <0.001
Spain -1.649 1.4478 -4.487 1.188 0.26
Japan 3.127 1.6099 -0.028 6.283 0.05
Hungary 0.332 1.7194 -3.038 3.702 0.85
Hours 1-6 H . ...
24 H 7.089 0.7367 5.645 8.533 <0.001
Dose Placebo . ... < 0 . 0 0 1
36 mg -9.236 1.1482 -11.487 -6.986 <0.001
72 mg -16.595 0.6769 -17.921 -15.268 <0.001
144 mg -20.929 0.9071 -22.0707 -19.151 <0.001
The index value was modelled by the hours, the country and the dose using a Generalized Estimating Equation model.
Figure 1 Fluorescence microscopy of E. coli gfp + strain cultured 
in urines of volunteers collected after cranberry powder con-
sumption and loaded on T24 epithelial cells. A. E. coli cultured in 
urines collected after placebo consumption; B. E. coli cultured in urines 
collected 6 h after consumption of cranberry powder containing 18 
mg proanthocyanidins (PAC); C. E. coli cultured in urines collected 6 h 
after consumption of cranberry powder containing 36 mg PAC; D. E. 
coli cultured in urines collected 6 h after consumption of cranberry 
powder containing 72 mg PAC.H
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Table 3: vivo kinetics of killing of C. elegans infected by E. coli grown in urine samples after consumption of the different proanthocyanidins regimens. 
A LT50 Median (IC95%) in days P
Regimen Placebo 18 mg 36 mg 72 mg Pl vs 18/36 18 vs 36 36 vs 72 6 h vs 24 h Sp-Fr vs 
Ja-Hu
Spain
1-6 h 3.5 [3-5] 5 [3-7] 6 [5-8] ND <0.001 <0.001 ND NS except for 
72 mg
24 h 3 [3-6] 4.5 [3-6] 5 [3-6] ND <0.001 NS ND <0.001
France <0.001
1-6 h 3 [3-5] 5 [4-7] 5.5 [4-7] ND <0.001 NS ND NS except for 
36 mg
24 h 3 [3-5] 3 [2-4] 5 [4-8] ND NS <0.001 ND <0.001
Japan
1-6 h 4 [3-5] ND 6.5 [5-9] 7 [5-9] <0.001 ND NS NS
24 h 4 [3-5] ND 5.5 [4-8] 6 [4-8] <0.001 ND NS
<0.001
Hungary
1-6 h 3 [3-5] ND 5 [4-8] 6 [5-10] <0.001 ND NS NS
24 h 4 [3-5] ND 5 [4-8] 6 [4-9] <0.001 ND NS
Total
1-6 h 3 [3-5] 5 [3-7] 5.5 [4-9] 6.5 [5-10] <0.001 NS <0.001 NS ND
24 h 3.5 [3-5] 4 [2-6] 5 [3-8] 6 [4-9] <0.001 <0.001 <0.001 ND
OP50 6 [6-7]H
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B LT100 Median 
(IC95%) in days
P
Regimen Placebo 18 mg 36 mg 72 mg Pl vs 18/36 18 vs 36 36 vs 72 6 h vs 24 h Sp-Fr vs Ja-
Hu
Spain
1-6 h 8.5 [7-8] 10 [9-10] 11.5 [11-12] ND <0.001 <0.001 ND NS except for 
72 mg
<0.001
24 h 7 [6-8] 9 [8-10] 9.5 [9-10] ND <0.001 NS ND <0.001
France
1-6 h 7 [6-8] 10 [9-11] 11 [10-12] ND <0.001 NS ND NS except for 
36 mg
24 h 7 [6-8] 8 [7-9] 10.5 [10-11] ND NS <0.001 ND <0.001
Japan <0.001
1-6 h 8 [7-8] ND 12.5 [12-13] 13 [12-14] <0.001 ND NS NS
24 h 7.5 [7-8] ND 11 [10-12] 12 [11-13] <0.001 ND NS
Hungary
1-6 h 7 [6-8] ND 12 [11-13] 12.5 [12-13] <0.001 ND NS NS
24 h 8 [7-8] ND 11 [10-12] 11.5 [11-12] <0.001 ND NS
Total
1-6 h 7 [6-8] 5 [3-7] 5.5 [4-9] 6.5 [5-10] <0.001 NS <0.001 NS ND
24 h 8 [7-8] 4 [2-6] 5 [3-8] 6 [4-9] <0.001 <0.001 <0.001 ND
OP50 14 [13-15]
(A) Determination of LT50 Median; (B) Determination of LT100 Median.
Table 3: vivo kinetics of killing of C. elegans infected by E. coli grown in urine samples after consumption of the different proanthocyanidins regimens.  (Continued)Howell et al. BMC Infectious Diseases 2010, 10:94
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relationship between consumed PAC and the virulence of
E. coli observed (P < 0.001) (Table 2). So, the effect of
PAC was "protective" for the worms. Moreover there was
an effect of hour on the virulence of E. coli. The virulence
of E. coli against worms was increased to 32% with urines
collected at 24 h compared to urines collected at 6 h (P <
0.001).
The number of E. coli CFU within the nematode gut
varied around 106 bacteria per worm for each strain 72 h
after ingestion without statistical difference (data not
shown) confirming the ingestion and proliferation of E.
coli isolates in the C. elegans intestine.
Discussion
I n  t h i s  s t u d y ,  t w o  e x p e r i m e n t a l  a s s a y s  w e r e  o p t i m i z e d
successfully to demonstrate bacterial anti-adhesion activ-
ity in human urines following cranberry powder con-
sumption. Two collection periods were chosen: 1-6 h
corresponding to the most important elimination period
of PAC in urines as previously demonstrated by Howell et
al. [11] and 24 h, the residual period of PAC elimination
in urines. Results for the MRHA assay were inversely cor-
related with the epithelial cell adhesion assay for the first
urines collected from 1-6 h after ingestion of the various
dosages of cranberry PAC equivalents (e.g. AI decreased
when anti-adhesion activity determined by MRHA
increased). However this correlation was not noted at 24
h, implying that the epithelial cell adhesion assay may be
more sensitive to detecting activity in urines when the
active metabolites are less concentrated. Our results sug-
gest that both the MRHA and the epithelial cell adhesion
assays could potentially be utilized to screen for urinary
anti-adhesion activity, especially in the first 6 h following
cranberry ingestion.
Adaptation of the cell adhesion assay using a fluores-
cent E. coli strain eliminates false positives observed in
previous experiments using Giemsa to stain bacteria
[12,13]. In the experimental protocol used in the present
study, the analysis is faster and easier than with Giemsa,
providing an improvement in quantification of bacterial
adhesion.
This multi-location randomized, double-blind versus
placebo study revealed a dose-dependent and time-
dependent effect in two different ex vivo models of E. coli
adherence to bladder epithelial cells. We demonstrated a
peak of urinary anti-adhesion activity 6 h after ingestion
of the PAC-standardized cranberry powder, with a reduc-
tion in activity at 24 h. There was a linear increase in uri-
nary anti-adhesion activity with increasing dosages of
PAC equivalents at both 6 h and 24 h. Interestingly a
residual anti-adhesion effect was shown 24 h after con-
sumption of 36 mg of PAC equivalents, with a more pro-
found effect after 72 mg. This effect was evident in urines
from all volunteers, regardless of country location. These
results highlighted for the first time that to achieve a bac-
terial anti-adhesion effect in urine, 36 mg of cranberry
PAC equivalents per day is effective, but 72 mg may offer
a nyctohemeral protection. The kinetic data indicate that
activity is highest after 6 h for both 36 and 72 mg, but
decreases significantly after 24 h, suggesting that it may
be beneficial to consume cranberry in two split doses of
36 mg in the morning and evening. With 72 mg of PAC,
the different metabolites of PAC (notably different antho-
cyanins [27]) are always present and efficient 24 h after
cranberry consumption. Further human trials are needed
to correlate the level of ex vivo anti-adhesion activity with
prevention of clinical UTI.
The pre-study background urines of several of the Japa-
nese volunteers exhibited anti-adhesion activity. This
phenomenon could be due to the production of endoge-
nous adhesion inhibitors (such as Tamm-Horsfall glyco-
protein) that are produced by some people. These
inhibitors are known to be transitory and can be induced
by a number of factors, dietary (on salt and water bal-
ance) and environmental. However, the AI in this popula-
tion was significantly higher compared to other
populations in multivariate analysis (p < 0.001). As the
influence of dosage and hour was suppressed in this anal-
ysis, this difference could be explained by the effect of
diets between the Asian and European lifestyles.
The PAC contained in cranberry inhibit E. coli adhesins
notably against P-fimbriae [3,7]. Adhesion is the first step
of bacterial virulence, to ensure the survival and establish
its replication. To demonstrate the effect of PAC on bac-
terial virulence, we used an in vivo killing nematode
model validated by different teams [12,25,26,28,29]. We
determined that the reduced ability of E. coli strain to kill
worms correlates with the consumption of cranberry cap-
sules. Bacteria grown in the urine of individuals consum-
ing the cranberry capsule are not able to adhere to the
worms and thus exhibit reduced killing of the worms in
spite of the presence and proliferation of E. coli strain in
the C. elegans intestine. E. coli were localized within the
nematode gut but could not exert any virulent effect
because they can establish any infection and loss of viru-
lence.
Conclusions
Administration of PAC-standardized cranberry powder
at dosages containing 72 mg of PAC per day may offer a
nyctohemeral protection against bacterial adhesion and
virulence in the urinary tract. Since bacterial adhesion is
the primary step in initiation of UTI, consumption of
cranberry may offer an additional means to help prevent
infections.
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